Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

 | Nov 06, 2017 | 9:23 AM EST
  • Comment
  • Print Print
  • Print
Stock quotes in this article:






Shares of Horizon Pharma plc (HZNP) rose 5.8% to $14.99 ahead of the market open on Monday, Nov. 6, after the Dublin-based firm unveiled better-than-expected third-quarter numbers and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

The company reported non-GAAP diluted earnings per share of $0.26, compared with $0.70 in the year-ago period. Net sales were $271.6 million, compared with $208.7 million in the same period in 2016.

Analysts had forecast, on average, non-GAAP EPS of $0.22 on sales of $259.7 million, according to FactSet Research Systems.

Horizon upped its full-year 2017 net sales guidance to $1.030 billion to $1.050, from the previously issued guidance of $1.010 billion to $1.045 billion. It also revised its adjusted Ebitda guidance to $350 million to $375 million from $340 million to $375 million.

Meanwhile, shares of Compugen Ltd. (CGEN) were up to 6.7% to $3.10 after the Holon, Israel-based firm said it was advancing COM902 into manufacturing in anticipation of filing an investigational new drug application in 2019. COM902 is Compugen's lead anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) antibody.

Compugen has signed a a process development and manufacturing service pact with Bayer HealthCare LLC to make COM902 for future use in clinical studies.

Among the other stock movers was BioCryst Pharmaceuticals Inc. (BCRX) . Shares of the Research Triangle Park, N.C.-based firm were up 7.3% to $5.02 ahead of the release of its third-quarter numbers on Nov. 7.

BioCryst is focused on developing treatment for rare diseases including certain types of cancer and other viruses.

Columnist Conversations

I recently highlighted WBA as one of the best values available in today's market. Walgreens ...
This trade is NOT for everyone (GE) came very close the 3/26 low @ 12.73 Gaps lower has been a recent daily e...
The support I needed to hold in XLB did not, so the trade is a bust......There may be some lower support at th...
British American Tobacco (BTI) is trading near multi-year lows, yielding 5.6% and about to ex-dividend on June...



News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.